TET2 controls chemoresistant slow-cycling cancer cell survival and tumor recurrenceIsabel Puig, Héctor G. Pálmer, Jordi Martínez‐Quintanilla et al.|Journal of Clinical Investigation|2018Cited by 108
Precision Oncology and Systemic Targeted Therapy in Pseudomyxoma PeritoneiJordi Martínez‐Quintanilla, McAllister Milly|Clinical Cancer Research|2024Cited by 15